



Claim 1. (Currently Amended) A compound of formula I






I

or a pharmaceutically acceptable salt thereof wherein:

A is a structure i, ii, ~~iii~~, or ~~iv~~



B is



W is NHC(=X)R₁, or -Y-het; X is O, or S; provided that when X is O, B is not the subsection (b);

Y is NH, O, or S;

Z is S(=O)(=N-R₅);

R₁ is

- (a) H,
- (b) NH₂,
- (c) NHC₁₋₄alkyl,
- (d) C₁₋₄alkyl,

- xi
- (e) C₂₋₄alkenyl,
 - (f) OC₁₋₄alkyl,
 - (g) SC₁₋₄alkyl, or
 - (h) (CH₂)_p C₃₋₆cycloalkyl;

at each occurrence, alkyl or cycloalkyl in R₁ is optionally substituted with one or more F, Cl or CN;

R₂ and R₃ are independently H, F, Cl, methyl or ethyl;

R₄ is H, CH₃, or F;

R₅ is

- (c) C(=O)C₁₋₄alkyl,
- (d) C(=O)OC₁₋₄alkyl,
- (e) C(=O)NHR₆, or
- (f) C(=S)NHR₆;

R₆ is H, C₁₋₄alkyl, or phenyl;

at each occurrence, alkyl in R₅ and R₆ is optionally substituted with one or more halo, CN, NO₂, phenyl, C₃₋₆ cycloalkyl, OR₇, C(=O)R₇, OC(=O)R₇, C(=O)OR₇, S(=O)_mR₇, S(=O)_mNR₇R₇, NR₇SO₂R₇, NR₇SO₂NR₇R₇, NR₇C(=O)R₇, C(=O)NR₇R₇, NR₇R₇, oxo, or oxime;

R₇ is H, C₁₋₄alkyl, or phenyl;

at each occurrence, phenyl is optionally substituted with one or more halo, ~~CF₃-CH₃~~, CN, NO₂, phenyl, C₃₋₆ cycloalkyl, OR₇, C(=O)R₇, OC(=O)R₇, C(=O)OR₇, S(=O)_mR₇, S(=O)_mNR₇R₇, NR₇SO₂R₇, NR₇SO₂NR₇R₇, NR₇C(=O)R₇, C(=O)NR₇R₇, or NR₇R₇; **when R₅ is C₁₋₄alkyl substituted with phenyl, the phenyl is additionally optionally substituted with CF₃ and CH₃;**

het is a C-linked five- (5) membered heteroaryl ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, or het is a C-linked six (6) membered heteroaryl ring having 1-3 nitrogen atoms;


p is 0, 1, or 2;

j is 1, 2, 3, 4, or 5; provided that j and p taken together are 2, 3, 4 or 5;

m is 0, 1, or 2; and

n is 2 or 3.

Claim 2. (Previously presented) A compound of claim 1 having the formula IA:



IA.

Claim 3. (Original) A compound of claim 2 wherein R₁ is C₁₋₄alkyl.

Claim 4. (Original) A compound of claim 2 wherein R₁ is ethyl.

Claim 5. (Original) A compound of claim 2 wherein R₁ is methyl.

Claim 6. (Original) A compound of claim 2 wherein R₁ is C₃₋₆cycloalkyl.

Claim 7. (Original) A compound of claim 2 wherein R₁ is cyclopropyl.

Claim 8. (Currently Amended) A compound of claim 2, 3, 4, 5, 6, or 7 wherein X is a sulfur atom.

Claim 9. (Currently Amended) A compound of claim 2, 3, 4, 5, 6, or 7 wherein X is an oxygen atom.


Claim 10. (Original) A compound of claim 8 wherein one of R₂ and R₃ is H, the other one is F.

Claim 11. (Original) A compound of claim 9 wherein one of R₂ and R₃ is H, the other one is F.

Claim 12. (Original) A compound of claim 8 wherein R₄ is H.

Claim 13. (Original) A compound of claim 9 wherein R_4 is H.


Claim 14. (Original) A compound of claim 8 wherein structure B is



wherein Z is $S(=O)(=NR_5)$.


Claim 15. (Canceled).

Claim 16. (Currently Amended) A compound of claim 8 wherein structure B is



wherein Z is $S(=O)(=NR_5)$.

Claim 17. (Original) A compound of claim 9 wherein structure B is



wherein Z is $S(=O)(=NR_5)$.

Claims 18-21. (Canceled).

Claim 22. (Original) A compound of claim 14 wherein R_5 is $C(=O)C_{1-4}alkyl$, $C(=O)OC_{1-4}alkyl$, $C(=O)NH_2$, or $C(=O)NHC_{1-4}alkyl$.

Claim 23. (Original) A compound of claim 22 wherein R_5 is $C(=O)NHCH_3$, or $C(=O)NHCH_2CH_3$.

Claim 24. (Original) A compound of claim 14 wherein R_5 is $C(=O)CH_3$.

Claim 25. (Original) A compound of claim 14 wherein R_3 is $C(=O)OCH_3$.

ε'
Claims 26-29. (Canceled).

Claim 30. (Original) A method for treating microbial infections comprising: administering to a mammal in need thereof an effective amount of a compound of formula I as shown in claim 1.

Claim 31. (Original) The method of claim 30 wherein said compound of formula I is administered orally, parenterally, transdermally, or topically in a pharmaceutical composition.

Claim 32. (Original) The method of claim 30 wherein said compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weight/day.

Claim 33. (Original) The method of claim 30 wherein said compound is administered in an amount of from about 1 to about 50 mg/kg of body weight/day.

Claim 34. (Original) A method for treating microbial infections of claim 30 wherein the infection is skin infection.

Claim 35. (Original) A method for treating microbial infections of claim 30 wherein the infection is eye infection.

Claim 36. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

Claim 37. (Canceled)

Claim 38. (Original) A compound of claim 16 wherein R_5 is $C(=O)C_{1-4}alkyl$, $C(=O)OC_{1-4}alkyl$, $C(=O)NH_2$, or $C(=O)NHC_{1-4}alkyl$.

ε'

Claim 39. (Original) A compound of claim 38 wherein R_5 is $C(=O)NHCH_3$, or $C(=O)NHCH_2CH_3$.

Claim 40. (Original) A compound of claim 16 wherein R_5 is $C(=O)CH_3$.

Claim 41. (Original) A compound of claim 16 wherein R_5 is $C(=O)OCH_3$.

Claim 42. (Original) A compound of claim 17 wherein R_5 is $C(=O)C_{1-4}alkyl$, $C(=O)OC_{1-4}alkyl$, $C(=O)NH_2$, or $C(=O)NHC_{1-4}alkyl$.

Claim 43. (Original) A compound of claim 42 wherein R_5 is $C(=O)NHCH_3$, or $C(=O)NHCH_2CH_3$.

Claim 44. (Original) A compound of claim 17 wherein R_5 is $C(=O)CH_3$.

Claim 45. (Original) A compound of claim 17 wherein R_5 is $C(=O)OCH_3$.

Claim 46. (Previously Presented) A compound of claim 2 which is

N-((5*S*)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1λ⁴-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide, *Z*-isomer;


N-((5*S*)-3-[3-fluoro-4-[1-(acetylimino)-1-oxidohexahydro-1λ⁴-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, *Z*-isomer;

N-((5*S*)-3-[3-fluoro-4-(1-[(methylamino)carbonyl]imino)-1-oxidohexahydro-1λ⁴-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, *Z*-isomer;

N-((5*S*)-3-[3-fluoro-4-(1-[(methoxycarbonyl]imino)-1-oxidohexahydro-1λ⁴-thiopyran-4-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, *Z*-isomer;

$\text{N}-((5S)-3-[3\text{-fluoro-4-(1-}[(\text{ethoxycarbonyl})\text{methyl}]\text{imino})-1\text{-oxido-}1\lambda^4\text{-thiopyran-4-yl)]phenyl}-2\text{-oxo-1,3-oxazolidin-5-yl})\text{methyl})\text{propanethioamide, Z-isomer;}$
 $\text{N}-((5S)-3-[3\text{-fluoro-4-(1-}[(\text{4-nitrophenyl})\text{amino}]\text{carbonyl}]\text{imino})-1\text{-oxido-}1\lambda^4\text{-thiopyran-4-yl)]phenyl}-2\text{-oxo-1,3-oxazolidin-5-yl})\text{methyl})\text{propanethioamide, Z-isomer;}$
 $\text{N}-((5S)-3-[3\text{-fluoro-4-(1-}[(\text{aminocarbonyl})\text{imino})-1\text{-oxido-}1\lambda^4\text{-thiopyran-4-yl)]phenyl}-2\text{-oxo-1,3-oxazolidin-5-yl})\text{methyl})\text{propanethioamide, Z-isomer;}$
 $\text{N}-((5S)-3-[3\text{-fluoro-4-(1-}[(\text{aminocarbonyl})\text{methyl}]\text{imino})-1\text{-oxido-}1\lambda^4\text{-thiopyran-4-yl)]phenyl}-2\text{-oxo-1,3-oxazolidin-5-yl})\text{methyl})\text{propanethioamide, Z-isomer;}$
 $\text{N}-[((5S)-3-[3\text{-fluoro-4-(1-}[(\text{methoxycarbonyl})\text{imino})-1\text{-oxido-}1\lambda^4\text{-4-thiazinan-4-yl)]phenyl}-2\text{-oxo-1,3-oxazolidin-5-yl})\text{methyl})\text{propanethioamide;}$
 $\text{N}-[((5S)-3-[3\text{-fluoro-4-(1-}[(\text{methoxycarbonyl})\text{imino})-1\text{-oxido-}1\lambda^4\text{-4-thiazinan-4-yl)]phenyl}-2\text{-oxo-1,3-oxazolidin-5-yl})\text{methyl})\text{cyclopropanecarbothioamide ;}$
 $\text{N}-[((5S)-3-[3\text{-fluoro-4-(1-}[(\text{methoxycarbonyl})\text{imino})-1\text{-oxido-}1\lambda^4\text{-thiopyran-4-yl)]phenyl}-2\text{-oxo-1,3-oxazolidin-5-yl})\text{methyl})\text{cyclopropanecarbothioamide, Z-isomer;}$
 $\text{N}-[((5S)-3-[3\text{-fluoro-4-(1-}[(\text{phenylmethoxy})\text{carbonyl}]\text{imino})-1\text{-oxido-}1\lambda^4\text{-thiopyran-4-yl)]phenyl}-2\text{-oxo-1,3-oxazolidin-5-yl})\text{methyl})\text{acetamide, Z-isomer; or}$
 $\text{N}-((5S)-3-[3\text{-fluoro-4-(1-}[(\text{benzylamino})\text{carbonyl}]\text{imino})-1\text{-oxido-}1\lambda^4\text{-thiopyran-4-yl)]phenyl}-2\text{-oxo-1,3-oxazolidin-5-yl})\text{methyl})\text{acetamide, Z-isomer.}$


Claim 47. (Currently amended) 4- A compound of formula II




II

or a pharmaceutically acceptable salt thereof wherein:

A is a structure ii



B is





W is $\text{NHC}(=\text{X})\text{R}_1$, or -Y-het;

X is O, or S;

Y is NH, O, or S;

Z is $\text{S}(=\text{O})(=\text{N}-\text{R}_5)$ and the B ring has the following stereochemistry



R_1 is

- (a) H,
- (b) NH_2 ,
- (c) $\text{NHC}_{1-4}\text{alkyl}$,
- (d) $\text{C}_{1-4}\text{alkyl}$,
- (e) $\text{C}_{2-4}\text{alkenyl}$,
- (f) $\text{OC}_{1-4}\text{alkyl}$,
- (g) $\text{SC}_{1-4}\text{alkyl}$, or

(h) $(CH_2)_p$ C₃₋₆cycloalkyl;

at each occurrence, alkyl or cycloalkyl in R₁ is optionally substituted with one or more F, Cl or CN;

R₂ and R₃ are independently H, F, Cl, methyl or ethyl;

R₄ is H, CH₃, or F;

R₅ is

- (a) H,
- (b) C₁₋₄alkyl,
- (c) C(=O)C₁₋₄alkyl,
- (d) C(=O)OC₁₋₄alkyl,
- (e) C(=O)NHR₆, or
- (f) C(=S)NHR₆;

R₆ is H, C₁₋₄alkyl, or phenyl;

at each occurrence, alkyl in R₅ and R₆ is optionally substituted with one or more halo, CN, NO₂, phenyl, C₃₋₆ cycloalkyl, OR₇, C(=O)R₇, OC(=O)R₇, C(=O)OR₇, S(=O)_mR₇, S(=O)_mNR₇R₇, NR₇SO₂R₇, NR₇SO₂NR₇R₇, NR₇C(=O)R₇, C(=O)NR₇R₇, NR₇R₇, oxo, or oxime;

R₇ is H, C₁₋₄alkyl, or phenyl;

at each occurrence, phenyl is optionally substituted with one or more halo, ~~CF₃, CH₃~~, CN, NO₂, phenyl, C₃₋₆ cycloalkyl, OR₇, C(=O)R₇, OC(=O)R₇, C(=O)OR₇, S(=O)_mR₇, S(=O)_mNR₇R₇, NR₇SO₂R₇, NR₇SO₂NR₇R₇, NR₇C(=O)R₇, C(=O)NR₇R₇, or NR₇R₇; **when R₅ is C₁₋₄alkyl**

substituted with phenyl, the phenyl is additionally optionally substituted with CF₃ and CH₃;

het is a C-linked five- (5) membered heteroaryl ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, or het is a C-linked six (6) membered heteroaryl ring having 1-3 nitrogen atoms;

p is 0, 1, or 2;

j is 1, 2, 3, 4, or 5; provided that j and p taken together are 2, 3, 4 or 5;

m is 0, 1, or 2;

~~and \equiv in structure iii is either a double bond or a single bond.~~

Claim 48. (Previously presented) The compound of claim 47 wherein R_1 is C_{1-4} alkyl.

Claim 49. (Previously presented) The compound of claim 47 wherein R_1 is ethyl.

81
Claim 50. (Previously presented) The compound of claim 47 wherein R_1 is methyl.

Claim 51. (Previously presented) The compound of claim 47 wherein R_1 is C_{3-6} cycloalkyl.

Claim 52. (Previously presented) The compound of claim 47 wherein R_1 is cyclopropyl.

Claim 53. (Currently Amended) The compound of claim 47 wherein X is a sulfur atom.

Claim 54. (Currently Amended) The compound of claim 47 wherein X is an oxygen atom.

Claim 55. (Previously Presented) The compound of claim 53 wherein one of R_2 and R_3 is H, the other one is F.

Claim 56. (Previously Presented) The compound of claim 54 wherein one of R_2 and R_3 is H, the other one is F.

Claim 57. (Previously presented) The compound of claim 47 wherein R_5 is H.

Claim 58. (Previously presented) The compound of claim 47 wherein R_5 is C_{1-4} alkyl, optionally substituted with OH; or C_{1-4} alkyl substituted with $C(=O)NHC_{1-4}$ alkyl, $C(=O)NH_2$ or phenyl; wherein the phenyl is optionally substituted with OH, methyl, NO_2 , CF_3 , or CN.

Claim 59. (Previously presented) The compound of claim 47 wherein R_5 is CH_3 , or ethyl.

Claim 60. (Previously presented) The compound of claim 47 wherein R₅ is C₁₋₄alkyl substituted with phenyl wherein the phenyl is optionally substituted with NO₂.

Claim 61. (Previously presented) The compound of claim 47 wherein R₅ is C(=O)C₁₋₄alkyl, C(=O)OC₁₋₄alkyl, C(=O)NH₂, or C(=O)NHC₁₋₄alkyl.

Claim 62. (Previously presented) The compound of claim 47 wherein R₅ is C(=O)NHCH₃, or C(=O)NHCH₂CH₃.

Claim 63. (Previously presented) The compound of claim 47 wherein R₅ is C(=O)CH₃.

Claim 64. (Previously presented) The compound of claim 47 wherein R₅ is C(=O)OCH₃.

Claim 65. (Previously presented) A compound of claim 47 which is

N-({(5*S*)-3-[3-fluoro-4-(1-imino-1-oxido-1,3,4-dihydro-2H-thiopyran-4-yl)]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide (*Z*)-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-imino-1-oxido-1,3,4-dihydro-2H-thiopyran-4-yl)]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)ethanethioamide (*Z*)-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-imino-1-oxido-1,3,4-dihydro-2H-thiopyran-4-yl)]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide (*Z*)-isomer;

N-({(5*S*)-3-[3-fluoro-4-(1-imino-1-oxido-1,3,4-dihydro-2H-thiopyran-4-yl)]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)cyclopropanethioamide (*Z*)-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-(acetylimino)-1-oxido-1,3,4-dihydro-2H-thiopyran-4-yl]]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-(methyylimino)-1-oxido-1,3,4-dihydro-2H-thiopyran-4-yl]]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, *Z*-isomer;

N-({(5*S*)-3-[3-fluoro-4-[1-(acetylimino)-1-oxido-1,3,4-dihydro-2H-thiopyran-4-yl]]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl)propanethioamide, *Z*-isomer;

$\text{N-}(\{(5S)\text{-}3\text{-}[3\text{-fluoro-}4\text{-}[1\text{-}(\text{ethylimino})\text{-}1\text{-oxido-}6\text{-hydro-}1\lambda^4\text{-thiopyran-}4\text{-yl)]phenyl}\text{-}2\text{-oxo-}1,3\text{-oxazolidin-}5\text{-yl}\}\text{methyl})\text{propanethioamide, } Z\text{-isomer;}$
 $\text{N-}(\{(5S)\text{-}3\text{-}[3\text{-fluoro-}4\text{-}[1\text{-}[(\text{phenylmethyl})\text{imino}]\text{-}1\text{-oxido-}6\text{-hydro-}1\lambda^4\text{-thiopyran-}4\text{-yl)]phenyl}\text{-}2\text{-oxo-}1,3\text{-oxazolidin-}5\text{-yl}\}\text{methyl})\text{propanethioamide, } Z\text{-isomer;}$
 $\text{N-}(\{(5S)\text{-}3\text{-}[3\text{-fluoro-}4\text{-}[1\text{-}[(3\text{-phenylpropyl})\text{imino}]\text{-}1\text{-oxido-}6\text{-hydro-}1\lambda^4\text{-thiopyran-}4\text{-yl)]phenyl}\text{-}2\text{-oxo-}1,3\text{-oxazolidin-}5\text{-yl}\}\text{methyl})\text{propanethioamide, } Z\text{-isomer;}$
 $\text{N-}(\{(5S)\text{-}3\text{-}[3\text{-fluoro-}4\text{-}(1\text{-}\{[(\text{methylamino})\text{carbonyl}]\text{imino}\}\text{-}1\text{-oxido-}6\text{-hydro-}1\lambda^4\text{-thiopyran-}4\text{-yl)]phenyl}\text{-}2\text{-oxo-}1,3\text{-oxazolidin-}5\text{-yl}\}\text{methyl})\text{propanethioamide, } Z\text{-isomer;}$
 $\text{N-}(\{(5S)\text{-}3\text{-}[3\text{-fluoro-}4\text{-}(1\text{-}[(\text{methoxycarbonyl})\text{imino}]\text{-}1\text{-oxido-}6\text{-hydro-}1\lambda^4\text{-thiopyran-}4\text{-yl)]phenyl}\text{-}2\text{-oxo-}1,3\text{-oxazolidin-}5\text{-yl}\}\text{methyl})\text{propanethioamide, } Z\text{-isomer;}$
 $\text{N-}(\{(5S)\text{-}3\text{-}[3\text{-fluoro-}4\text{-}(1\text{-}[[(\text{ethoxycarbonyl})\text{methyl}]\text{imino}]\text{-}1\text{-oxido-}6\text{-hydro-}1\lambda^4\text{-thiopyran-}4\text{-yl)]phenyl}\text{-}2\text{-oxo-}1,3\text{-oxazolidin-}5\text{-yl}\}\text{methyl})\text{propanethioamide, } Z\text{-isomer;}$
 $\text{N-}(\{(5S)\text{-}3\text{-}[3\text{-fluoro-}4\text{-}(1\text{-}\{[(4\text{-nitrophenyl})\text{amino}]\text{carbonyl}]\text{imino}\}\text{-}1\text{-oxido-}6\text{-hydro-}1\lambda^4\text{-thiopyran-}4\text{-yl)]phenyl}\text{-}2\text{-oxo-}1,3\text{-oxazolidin-}5\text{-yl}\}\text{methyl})\text{propanethioamide, } Z\text{-isomer ;}$
 $\text{N-}(\{(5S)\text{-}3\text{-}[3\text{-fluoro-}4\text{-}[1\text{-}[(\text{aminocarbonyl})\text{imino}]\text{-}1\text{-oxido-}6\text{-hydro-}1\lambda^4\text{-thiopyran-}4\text{-yl)]phenyl}\text{-}2\text{-oxo-}1,3\text{-oxazolidin-}5\text{-yl}\}\text{methyl})\text{propanethioamide, } Z\text{-isomer;}$
 $\text{N-}(\{(5S)\text{-}3\text{-}[3\text{-fluoro-}4\text{-}[1\text{-}[[(\text{aminocarbonyl})\text{methyl}]\text{imino}]\text{-}1\text{-oxido-}6\text{-hydro-}1\lambda^4\text{-thiopyran-}4\text{-yl)]phenyl}\text{-}2\text{-oxo-}1,3\text{-oxazolidin-}5\text{-yl}\}\text{methyl})\text{propanethioamide, } Z\text{-isomer;}$
 $\text{N-}(\{(5S)\text{-}3\text{-}[3\text{-fluoro-}4\text{-}[1\text{-}[(2\text{-hydroxyethyl})\text{imino}]\text{-}1\text{-oxido-}6\text{-hydro-}1\lambda^4\text{-thiopyran-}4\text{-yl)]phenyl}\text{-}2\text{-oxo-}1,3\text{-oxazolidin-}5\text{-yl}\}\text{methyl})\text{propanethioamide, } Z\text{-isomer;}$
 $\text{N-}(\{(5S)\text{-}3\text{-}[3\text{-fluoro-}4\text{-}[1\text{-}(\text{methylimino})\text{-}1\text{-oxido-}6\text{-hydro-}1\lambda^4\text{-thiopyran-}4\text{-yl)]phenyl}\text{-}2\text{-oxo-}1,3\text{-oxazolidin-}5\text{-yl}\}\text{methyl})\text{cyclopropanecarbothioamide, } Z\text{-isomer;}$
 $\text{N-}[\{(5S)\text{-}3\text{-}\{3\text{-fluoro-}4\text{-}[1\text{-}[(\text{methoxycarbonyl})\text{imino}]\text{-}1\text{-oxido-}6\text{-hydro-}1\lambda^4\text{-thiopyran-}4\text{-yl)]phenyl}\text{-}2\text{-oxo-}1,3\text{-oxazolidin-}5\text{-yl}\}\text{methyl}]\text{cyclopropanecarbothioamide, } Z\text{-isomer;}$
 $\text{N-}[\{(5S)\text{-}3\text{-}\{3\text{-fluoro-}4\text{-}[1\text{-}[(\text{phenylmethoxy})\text{carbonyl}]\text{imino}]\text{-}1\text{-oxido-}6\text{-hydro-}1\lambda^4\text{-thiopyran-}4\text{-yl)]phenyl}\text{-}2\text{-oxo-}1,3\text{-oxazolidin-}5\text{-yl}\}\text{methyl}]\text{acetamide, } Z\text{-isomer; or}$
 $\text{N-}(\{(5S)\text{-}3\text{-}[3\text{-fluoro-}4\text{-}(1\text{-}\{[(\text{benzylamino})\text{carbonyl}]\text{imino}\}\text{-}1\text{-oxido-}6\text{-hydro-}1\lambda^4\text{-thiopyran-}4\text{-yl)]phenyl}\text{-}2\text{-oxo-}1,3\text{-oxazolidin-}5\text{-yl}\}\text{methyl})\text{acetamide, } Z\text{-isomer.}$

E! Claim 66. (Currently Amended) A method for treating microbial infections comprising:
administering to a mammal in need thereof an effective amount of a compound of formula II as
shown in claim 47.
